"In light of nonrandomized studies suggesting benefit of video-assisted thoracoscopic partial pleurectomy (VAT-PP) in symptom control and survival, Rintoul et al performed a randomized trial (MesoVATS) of VAT-PP vs talc pleurodesis in malignant pleural mesothelioma. As reported in The Lancet, this UK study showed no survival improvement, more frequent complications, and longer hospital stay with VAT-PP."
Editor's note: A study with volunteer mesothelioma patients aimed to compare two treatments: video-assisted thoracoscopic partial pleurectomy (VAT-PP) and talc pleurodesis. All patients in the trial had malignant pleural mesothelioma with pleural effusion. The researchers wished to figure out which treatment was better in terms of symptom control and survival. They found that, between the two treatments, there was no significant difference in the number of patients still alive one year later. Also, patients treated with VAT-PP had more frequent complications and longer hospital stays.